Teva Pharmaceutical Industries Limited TEVJF Stock
Teva Pharmaceutical Industries Limited Price Chart
Teva Pharmaceutical Industries Limited TEVJF Financial and Trading Overview
| Teva Pharmaceutical Industries Limited stock price | 30.34 USD |
| Previous Close | 28.36 USD |
| Open | 37 USD |
| Bid | 28.31 USD x 10000 |
| Ask | 36.51 USD x 10000 |
| Day's Range | 37 - 37 USD |
| 52 Week Range | 14 - 37 USD |
| Volume | 17 USD |
| Avg. Volume | 6 USD |
| Market Cap | 43.08B USD |
| Beta (5Y Monthly) | 0.863 |
| PE Ratio (TTM) | 27.61194 |
| EPS (TTM) | 1.34 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | November 28, 2017 |
| 1y Target Est | N/A |
TEVJF Valuation Measures
| Enterprise Value | 48.34B USD |
| Trailing P/E | 27.61194 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 0.74 |
| Price/Sales (ttm) | 2.4833593 |
| Price/Book (mrq) | 5.236343 |
| Enterprise Value/Revenue | 2.786 |
| Enterprise Value/EBITDA | 9.663 |
Trading Information
Teva Pharmaceutical Industries Limited Stock Price History
| Beta (5Y Monthly) | 0.863 |
| 52-Week Change | 69.60% |
| S&P500 52-Week Change | 27.18% |
| 52 Week High | 37 USD |
| 52 Week Low | 14 USD |
| 50-Day Moving Average | 29.03 USD |
| 200-Day Moving Average | 25.13 USD |
TEVJF Share Statistics
| Avg. Volume (3 month) | 6 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 1.16B |
| Float | 1.08B |
| Short Ratio | N/A |
| % Held by Insiders | 2.17% |
| % Held by Institutions | 21.27% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | 105.00% |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 9.02% |
| Operating Margin (ttm) | 19.16% |
| Gross Margin | 52.06% |
| EBITDA Margin | 28.83% |
Management Effectiveness
| Return on Assets (ttm) | 6.38% |
| Return on Equity (ttm) | 21.59% |
Income Statement
| Revenue (ttm) | 17.35B USD |
| Revenue Per Share (ttm) | 15.09 USD |
| Quarterly Revenue Growth (yoy) | 2.29% |
| Gross Profit (ttm) | 9.03B USD |
| EBITDA | 5B USD |
| Net Income Avi to Common (ttm) | 1.56B USD |
| Diluted EPS (ttm) | 1.34 |
| Quarterly Earnings Growth (yoy) | 72.39% |
Balance Sheet
| Total Cash (mrq) | 3.74B USD |
| Total Cash Per Share (mrq) | 3.21 USD |
| Total Debt (mrq) | 16.92B USD |
| Total Debt/Equity (mrq) | 205.6 USD |
| Current Ratio (mrq) | 1.013 |
| Book Value Per Share (mrq) | 7.066 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.71B USD |
| Levered Free Cash Flow (ttm) | 2.61B USD |
Profile of Teva Pharmaceutical Industries Limited
| Country | United States |
| State | N/A |
| City | Tel Aviv-Yafo |
| Address | 124 Dvora HaNevi’a St. |
| ZIP | 6944020 |
| Phone | 972 3 914 8213 |
| Website | https://www.tevapharm.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 31173 |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Q&A For Teva Pharmaceutical Industries Limited Stock
What is a current TEVJF stock price?
Teva Pharmaceutical Industries Limited TEVJF stock price today per share is 30.34 USD.
How to purchase Teva Pharmaceutical Industries Limited stock?
You can buy TEVJF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Teva Pharmaceutical Industries Limited?
The stock symbol or ticker of Teva Pharmaceutical Industries Limited is TEVJF.
Which industry does the Teva Pharmaceutical Industries Limited company belong to?
The Teva Pharmaceutical Industries Limited industry is Drug Manufacturers - Specialty & Generic.
How many shares does Teva Pharmaceutical Industries Limited have in circulation?
The max supply of Teva Pharmaceutical Industries Limited shares is 1.16B.
What is Teva Pharmaceutical Industries Limited Price to Earnings Ratio (PE Ratio)?
Teva Pharmaceutical Industries Limited PE Ratio is 22.64179000 now.
What was Teva Pharmaceutical Industries Limited earnings per share over the trailing 12 months (TTM)?
Teva Pharmaceutical Industries Limited EPS is 1.34 USD over the trailing 12 months.
Which sector does the Teva Pharmaceutical Industries Limited company belong to?
The Teva Pharmaceutical Industries Limited sector is Healthcare.


